2025-05-16 - Analysis Report
Okay, here's the analysis of Teva Pharmaceutical Industries Ltd ADR (TEVA) based on the provided data.

**Report on Teva Pharmaceutical Industries Ltd ADR (TEVA)**

**1. Relative Performance vs. S&P 500 (VOO)**

*   **Ticker:** TEVA
*   **Company:** Teva Pharmaceutical Industries Ltd ADR
*   **Description:** Teva is a global pharmaceutical company specializing in generic and specialty medicines.
*   **TEVA Cumulative Return:** 57.66%
*   **VOO Cumulative Return:** 81.82%
*   **Absolute Deviation:** -24.17%
*   **Deviation Range:** Max: 21.9, Min: -122.3, Current Relative Deviation: 68.0

**Analysis:** TEVA has underperformed the S&P 500 (VOO) over the observed period, with a cumulative return difference of -24.17%. The relative deviation of 68.0 indicates that TEVA's current underperformance, compared to its historical range, is closer to the better end of its historical underperformance.  It's important to remember this isn't "outperformance" but a position relative to its *past* performance compared to the VOO.

**Alpha, Beta Analysis**

| Year       | CAGR   | MDD   | Alpha   | Beta   | Cap(B) |
| ---------- | ------ | ----- | ------- | ------ | ------ |
| 2015-2017  | -44.0% | 58.4% | -73.0%  | -0.0  | 22.0   |
| 2016-2018  | -41.0% | 70.4% | -59.0%  | -0.1  | 17.9   |
| 2017-2019  | -16.0% | 70.4% | -45.0%  | -0.2  | 11.4   |
| 2018-2020  | 0.0%  | 70.4% | -25.0%  | -0.2  | 11.2   |
| 2019-2021  | -22.0% | 58.3% | -76.0%  | -0.2  | 9.3    |
| 2020-2022  | 27.0%  | 74.8% | 20.0%   | -0.2  | 10.6   |
| 2021-2023  | 38.0%  | 74.8% | 21.0%   | -0.8  | 12.1   |
| 2022-2024  | 122.0% | 74.8% | 106.0%  | -0.7  | 25.6   |
| 2023-2025  | 68.0%  | 76.0% | 38.0%   | 0.1   | 19.8   |

**Analysis:**

*   **CAGR (Compound Annual Growth Rate):**  Shows volatile performance with periods of significant negative growth followed by strong positive growth in recent years.
*   **MDD (Maximum Drawdown):** Indicates high risk, with MDD consistently high throughout the periods.
*   **Alpha:**  Generally negative alpha indicates underperformance relative to the benchmark, except for recent periods (2020-2025) where positive alpha suggests outperformance.
*   **Beta:** Beta values mostly close to zero or negative suggest that the stock has low correlation with the market.
*   **Cap(B):** Market capitalization shows that the company's size varies over time.

**2. Recent Price Action**

*   **Current Price:** 17.045
*   **Last Market Data:** Price: 17.055, Previous Close: 16.89, Change: 0.98%
*   **5-day Moving Average:** 17.521
*   **20-day Moving Average:** 15.4953
*   **60-day Moving Average:** 15.5799

**Analysis:**

*   The stock price increased by 0.98% in the last trading session, suggesting a positive momentum.
*   The current price is below the 5-day moving average but above both the 20-day and 60-day moving averages.  This *could* indicate a recent short-term pullback after a longer-term uptrend. However, the 5-day MA is very close, so this signal is weak.

**3. Market Risk Indicator & Expected Return**

*   **Market Risk Indicator (MRI):** 0.35 (Low Risk)
*   **RSI:** 68.26 (Approaching Overbought Territory)
*   **PPO:** 1.81
*   **Recent (20-day) Relative Deviation Change:** -0.2 (Short-term Decline)
*   **Significant Price Change:** The price increase of 0.98% compared to the previous close could reflect recent news or market sentiment shifts.
*   **Expected Return:** -34.9% (Long-term, relative to S&P 500)

**Analysis:**

*   The MRI suggests low market risk.
*   The RSI approaching 70, hints at potential overbought conditions.
*   A negative expected return indicates that, based on the model, long-term investment in TEVA may underperform the S&P 500.  The high negative value (-34.9%) is a significant concern.

**4. Recent News & Significant Events**

*   **2025-05-15:** Business developments, regulatory changes, or market events.
*   **2025-05-12:** Analyst discussions on performance and outlook.
*   **2025-05-13:** Notable stock volatility.
*   **2025-05-16:** Market expert advice to monitor news and company announcements.

**Analysis:** The recent news suggests that TEVA is experiencing notable events, potential volatility, and analyst scrutiny. Investors should closely monitor company announcements and news releases.

**5. Recent Earnings Analysis**

| 날짜       | EPS    | 매출       |
| ---------- | ------ | ---------- |
| 2025-05-07 | 0.19   | 3.89 B$    |
| 2024-11-06 | -0.39  | 4.33 B$    |
| 2024-07-31 | -0.75  | 4.16 B$    |
| 2024-05-08 | -0.12  | 3.82 B$    |
| 2025-05-07 | -0.12  | 3.82 B$    |

**Analysis:**

*   The most recent EPS (2025-05-07) is positive (0.19), a significant improvement over previous quarters.
*   Revenue has fluctuated, with a recent decrease to 3.89 B$.

**6. Financial Information**

**Revenue and Profitability:**

| Quarter    | Revenue  | Profit Margin |
| ---------- | -------- | ------------- |
| 2025-03-31 | $3.89B  | 48.24%        |
| 2024-12-31 | $4.23B  | 50.15%        |
| 2024-09-30 | $4.33B  | 49.60%        |
| 2024-06-30 | $4.16B  | 48.61%        |
| 2024-03-31 | $3.82B  | 46.37%        |

**Capital and Profitability:**

| Quarter    | Equity  | ROE      |
| ---------- | ------- | -------- |
| 2025-03-31 | $6.26B | 3.42%    |
| 2024-12-31 | $5.37B | -4.04%   |
| 2024-09-30 | $6.07B | -7.21%   |
| 2024-06-30 | $6.36B | -13.30%  |
| 2024-03-31 | $7.28B | -1.91%   |

**Analysis:**

*   **Revenue and Profitability:** Revenue has been relatively stable over the past year, with profit margins consistently high, around 48-50%.
*   **Capital and Profitability:** Equity has fluctuated. The recent ROE is positive, suggesting improved profitability compared to previous quarters, which were negative.

**7. Overall Summary**

TEVA presents a mixed picture.  The company has underperformed the S&P 500 significantly over the period examined, though its *relative* deviation from the S&P is closer to the better end of its historical range. Recent performance indicators show some positive signs, including a recent positive EPS, high profit margins, and an increase in the stock price. However, the RSI approaching overbought territory and a negative expected return raise concerns. The company has experienced periods of significant revenue growth and periods of loss. The recent analyst discussions and news about volatility suggest that the stock is subject to change and that close monitoring is crucial.

**Investment Recommendation:**  Due to the negative expected return, historical underperformance, and recent news-driven volatility, a cautious approach is advised. Investors should thoroughly research the company's prospects, monitor upcoming earnings and news, and consider their risk tolerance before making any investment decisions. The recent positive EPS is a potential indicator of a turnaround, but further confirmation is needed.
